Zug, Switzerland, February 14, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it is offering to sell common shares and warrants to purchase its common shares in an underwritten public offering pursuant to an effective registration statement on Form F-3 filed with the Securities and Exchange Commission (SEC). The common shares and warrants are being sold in units. In connection with this offering, the Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the common shares and/or warrants sold in the offering.
All of the common shares and warrants are being offered by the Company. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
Roth Capital Partners, LLC is acting as sole book-running manager for the proposed offering.
A registration statement relating to these securities has been filed with the SEC and was declared effective on September 10, 2015. Before you invest, you should read the preliminary prospectus supplement and accompanying base prospectus and the other documents the Company has filed with the SEC for more complete information about the Company and this offering.
The offering will be made only by means of a prospectus supplement. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from Roth Capital Partners, LLC at 888 San Clemente Drive, Newport Beach, CA 92660 or by calling 1-800-678-9147, or by accessing the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing intranasal betahistine for Meniere’s disease and vestibular vertigo (AM-125) and early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol “EARS.”
